Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb extends Syngene International research alliance

Bristol-Myers Squibb extends Syngene International research alliance

5th June 2014

Bristol-Myers Squibb has announced an extension to its alliance with Syngene International, India's largest contract research organisation.

The five-year extension of their drug discovery and development collaboration builds on a relationship that has been ongoing since 2007.

Working with Syngene and its corporate parent Biocon, Bristol-Myers Squibb has been able to develop integrated capabilities in medicinal and process chemistry, biology, biotechnology, biomarkers, drug metabolism and pharmacokinetics, analytical research, and pharmaceutical development.

Thanks to the collaboration, six drug candidates have been produced for further study, while Bristol-Myers Squibb has also been able to reduce the time and costs associated with advancing new compounds to first-in-human studies.

Francis Cuss, executive vice-president and chief scientific officer at Bristol-Myers Squibb, said: "The BBRC has supported the nonclinical development of a large proportion of our small-molecule portfolio assets since its inception, and is a premier example of the high-quality innovative drug hunting that is taking place in India today."

This comes after the company allied with Incyte on the development of a new combination immunotherapy regimen last month.ADNFCR-8000103-ID-801725988-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.